EUCTR2013-001080-23-ES进行中（未招募）不适用
Rifaximin associated with the classic triple therapy (inhibitor proton pump, amoxicillin and clarithromycin) for eradication of Helicobacter pylori infection - R+OCA
Javier P. Gisbert0 个研究点目标入组 40 人开始时间: 2014年2月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.- Age more than or equal to 18 years
- •2.- Dyspeptic patients with persistent or recurrent symptoms, with
- •demonstrated H. pylori infection.
- •3.- Having been prescribed the standard triple therapy eradication
- •therapy by routine clinical practice.
- •4.- Haven't begun taking the eradication treatment yet.
- •5.- Written informed consent of the patient.
- •6.- The five first patient included in the study must have a blood test scheduled from the outpatient clinic, in the month after the treatment is finished.
- •7.- If the patient is a woman of childbearing age, is asked to commit to
- •not get pregnant or t use adequate contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 40
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •1.- Previouse Eradication therapy for H. pylori
- •2.- Allergy to any of the antibiotic used in the treatment.
- •3.- Taking antibiotics or bismuth salts after conducting the breath test.
- •4.- Previous gastric surgery.
- •5.- Presence of pulmonary, hepatic, renal, endocrine, metabolic,
- •hematologic or tumoral severe disease.
- •6.- Very advanced chronic disease or any other condition that prevents
- •attending to monitoring and control visits.
- •7.- History of drug or alcohol abuse.
- •8.- Patients who are pregnant or lactating.
研究者
相似试验
招募中
3 期
Combination of rifaximin, plasma exchange, and stem cell based therapy for severe alcoholic hepatitisCTRI/2023/04/052118PGIMER, Chandigarh
尚未招募
Unknown
The effect of Rifaximin (an antibiotic drug commonly used in liver failure patients) and standard medical therapy vs standard medical therapy alone on myosteatosis (fat deposition in abdominal muscles), in patients with decompensated cirrhosis- a randomized controlled trialCTRI/2024/07/069984PGIMER, CHANDIGARH
招募中
3 期
The effect of rifaximin in IBSIrritable bowel syndrome.Irritable bowel syndromeIRCT20221211056775N1Arak University of Medical Sciences60
已完成
3 期
The effect of rifaximin in different doses on symptoms and quality of life improvement in Iranian patients with diarrhea-predominant irritable bowel syndromeIrritable bowel syndrome with diarrheaIRCT20141201020178N11Iran University of Medical Sciences200
进行中（未招募）
1 期
Rifaximin in the prevention of alcoholic liver diseaseEUCTR2014-001856-51-DKAleksander Krag136